Clinical trial · Observational
LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Liquid Biopsies in Patients With Advanced Non-small Cell Lung Cancer
NCT02511288CI-TRIAL-00080043LIBILrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- Cohort 1
- description
- Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis
- label
- Cohort 2
- description
- Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis
- label
- Cohort 3
- description
- Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)
Primary outcomes (1)
- measure
- Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA)
- timeFrame
- 5 years
- description
- Technique: ddPCR + targeted NGF, whole exome sequencing
Secondary outcomes (8)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
COHORT 1 Inclusion Criteria: * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status * Inclusion at the time of diagnostic * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent Exclusion Criteria: \- Patients treated before their liquid biopsy COHORT 2 Inclusion criteria * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement. * Inclusion at the time of diagnosis * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent COHORT 3 Inclusion criteria * Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status. * Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line) * Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report * Age ≥ 18 years * Covered by a health insurance * Signed consent Exclusion criteria \- Initiation of immunotherpy before their liquid biopsy
References
Publications (0)
Data not yet available
No reference posted for this study.